The efficacy and safety of apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis

BACKGROUND: Apatinib is a small-molecule tyrosine kinase inhibitor targeting VEGFR-2, which was recently used in a phase II clinical trial for the treatment of recurrent or metastatic nasopharyngeal carcinoma (rmNPC). However, there is no consistent conclusion on its efficacy and safety on rmNPC. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Huixiong, Weng, Xiangqian, Wu, Xiangji, Wu, Lizhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273677/
https://www.ncbi.nlm.nih.gov/pubmed/35836539
http://dx.doi.org/10.21037/tcr-22-1467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273677/
https://www.ncbi.nlm.nih.gov/pubmed/35836539
http://dx.doi.org/10.21037/tcr-22-1467

Ejemplares similares